Regulus floats after slashing IPO price but partner placements add to tally

Regulus Therapeutics sold 11.25 million shares of common stock at $4 per share on 4 October - one-third of its earlier expectation of $10 to $12 per share - when its initial public offering debuted on the Nasdaq, but the company raised $70 million in total thanks to a concurrent private placement of 6.25 million shares with its partner AstraZeneca.